Natural history and staging of chronic myelogenous leukaemia

J. Cortes, H. M. Kantarjian, S. Giralt, M. Talpaz

Research output: Contribution to journalArticle

Abstract

The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.

Original languageEnglish (US)
Pages (from-to)277-290
Number of pages14
JournalBailliere's Clinical Haematology
Volume10
Issue number2
DOIs
StatePublished - Jan 1 1997
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Natural History
Interferons
Cytogenetics
Early Diagnosis
Clone Cells
Therapeutics

Keywords

  • Chronic myoloid leukaemia
  • Cytogenetic response
  • Interferon
  • Prognosis
  • Stage

ASJC Scopus subject areas

  • Hematology

Cite this

Natural history and staging of chronic myelogenous leukaemia. / Cortes, J.; Kantarjian, H. M.; Giralt, S.; Talpaz, M.

In: Bailliere's Clinical Haematology, Vol. 10, No. 2, 01.01.1997, p. 277-290.

Research output: Contribution to journalArticle

Cortes, J. ; Kantarjian, H. M. ; Giralt, S. ; Talpaz, M. / Natural history and staging of chronic myelogenous leukaemia. In: Bailliere's Clinical Haematology. 1997 ; Vol. 10, No. 2. pp. 277-290.
@article{33a0bb97bd514751a822f62eabf13db6,
title = "Natural history and staging of chronic myelogenous leukaemia",
abstract = "The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.",
keywords = "Chronic myoloid leukaemia, Cytogenetic response, Interferon, Prognosis, Stage",
author = "J. Cortes and Kantarjian, {H. M.} and S. Giralt and M. Talpaz",
year = "1997",
month = "1",
day = "1",
doi = "10.1016/S0950-3536(97)80007-8",
language = "English (US)",
volume = "10",
pages = "277--290",
journal = "Bailliere's Clinical Haematology",
issn = "0950-3536",
publisher = "Bailliere Tindall Ltd",
number = "2",

}

TY - JOUR

T1 - Natural history and staging of chronic myelogenous leukaemia

AU - Cortes, J.

AU - Kantarjian, H. M.

AU - Giralt, S.

AU - Talpaz, M.

PY - 1997/1/1

Y1 - 1997/1/1

N2 - The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.

AB - The natural history of chronic myelogenous leukaemia has changed in recent years, partly as a result of earlier diagnosis but mostly as a consequence of the availability of effective therapies that have the potential to eradicate the Philadelphia-positive clone. The prognostic models designed in the pre-interferon-α (IFN-α) era based on clinical characteristics of the disease are still useful in identifying different risk groups after treatment with IFN-α, but achieving a cytogenetic response with IFN-α is now the most important prognostic factor for survival. The significance of other molecular and biological variables remains to be determined.

KW - Chronic myoloid leukaemia

KW - Cytogenetic response

KW - Interferon

KW - Prognosis

KW - Stage

UR - http://www.scopus.com/inward/record.url?scp=0030756485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030756485&partnerID=8YFLogxK

U2 - 10.1016/S0950-3536(97)80007-8

DO - 10.1016/S0950-3536(97)80007-8

M3 - Article

C2 - 9376664

AN - SCOPUS:0030756485

VL - 10

SP - 277

EP - 290

JO - Bailliere's Clinical Haematology

JF - Bailliere's Clinical Haematology

SN - 0950-3536

IS - 2

ER -